Senores Pharmaceuticals Ltd's Q3FY25 Quarter Results
- 24 Jan 2025
Result Summary
- Senores Pharmaceuticals Ltd reported a - quarter-on-quarter (QoQ) - in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 36.1%.
- Its expenses for the quarter were - by - QoQ and up 26.6% YoY.
- The net profit - - QoQ and increased 130.8% YoY.
- The earnings per share (EPS) of Senores Pharmaceuticals Ltd stood at 5 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 108.18 | 0.00 | 79.50 | - | 36.1% |
Total Expenses | 87.69 | 0.00 | 69.24 | - | 26.6% |
Profit Before Tax | 20.49 | - | 10.26 | NaN% | 99.7% |
Tax | 4.06 | 0.00 | 3.14 | - | 29.3% |
Profit After Tax | 16.43 | 0.00 | 7.12 | - | 130.8% |
Earnings Per Share | 5.00 | 0.00 | 3.50 | - | 42.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Senores Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, production, and marketing of pharmaceutical products. The company specializes in manufacturing generic drugs and has established a robust presence in both domestic and international markets. While specific recent developments about the company were not provided, it is understood that Senores Pharmaceuticals is committed to expanding its product portfolio and enhancing its market reach. The company is known for its focus on quality and affordability, catering to a diverse range of therapeutic areas.
Revenue
For the third quarter of fiscal year 2025 (Q3FY25), Senores Pharmaceuticals Ltd reported a total income of ₹108.18 crores. This represents a significant increase of 36.1% compared to the same quarter in the previous fiscal year (Q3FY24), where the total income was ₹79.50 crores. This notable year-over-year growth indicates robust performance in terms of revenue generation. The data for the preceding quarter (Q2FY25) was not provided, hence quarter-over-quarter comparison is not possible from the provided data. The increase in total income highlights the company's ability to enhance its revenue streams over the year.
Profitability
In Q3FY25, Senores Pharmaceuticals Ltd achieved a profit before tax of ₹20.49 crores, which marks a substantial increase of 99.7% from the ₹10.26 crores recorded in Q3FY24. After accounting for tax expenses, the profit after tax for Q3FY25 stood at ₹16.43 crores, showcasing an impressive year-over-year growth of 130.8% from ₹7.12 crores in Q3FY24. The tax component in this quarter was ₹4.06 crores, representing a 29.3% increase from the previous year's same quarter. The earnings per share (EPS) for Q3FY25 was ₹5.00, which is a 42.9% increase over the EPS of ₹3.50 in Q3FY24. These figures reflect a strong profitability performance compared to the previous year, with significant increases in both profit before and after tax.
Operating Metrics
The total expenses for Senores Pharmaceuticals Ltd in Q3FY25 amounted to ₹87.69 crores, which increased by 26.6% compared to ₹69.24 crores in Q3FY24. The data for Q2FY25 is unavailable, making a quarter-over-quarter analysis not feasible. The increase in expenses corresponds with the rise in total income, suggesting an expansion in operational activities. The company has demonstrated efficient cost management, as reflected in the growth of its profit margins. While specific operating metrics beyond these financial figures were not provided, the available data indicates increased operational scale and investment in business activities.
